CoChat

Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study.

Open access
Tran, Duong Thuy, Preen, David B., Einarsdottir, Kristjana, Kemp-Casey, Anna, Randall, Deborah, Jorm, Louisa R., Choi, Stephanie K. Y., Havard, Alys · 2020 · BMC Medicine

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Abstract

Background: Varenicline, bupropion and nicotine replacement therapy (NRT) are three effective pharmacotherapies for smoking cessation, but data about their safety in pregnancy are limited. We assessed the risk of adverse perinatal outcomes and major congenital anomalies associated with the use of these therapies in pregnancy in Australia. Methods: Perinatal data for 1,017,731 deliveries (2004 to 2012) in New South Wales and Western Australia were linked to pharmaceutical dispensing, hospital admission and death records. We identified 97,875 women who smoked during pregnancy; of those, 233, 330 and 1057 were exposed to bupropion, NRT and varenicline in pregnancy, respectively. Propensity scores were used to match exposed women to those who were unexposed to any smoking therapy (1:10 ratio). Propensity scores and gestational age at exposure were used to match varenicline-exposed to NRT-exposed women (1:1 ratio). Time-dependent Cox proportional hazards models estimated hazard ratios (HR) with 95% confidence intervals (95% CI) for any adverse perinatal event (a composite of 10 unfavourable maternal and neonatal outcomes) and any major congenital anomaly. Results: The risk of any adverse perinatal event was not significantly different between bupropion-exposed and unexposed women (39.2% versus 39.3%, HR 0.93, 95% CI 0.73–1.19) and between NRT-exposed and unexposed women (44.8% vs 46.3%, HR 1.02, 95% CI 0.84–1.23), but it was significantly lower in women exposed to varenicline (36.9% vs 40.1%, HR 0.86, 95% CI 0.77–0.97). Varenicline-exposed infants were less likely than unexposed infants to be born premature (6.5% vs 8.9%, HR 0.72, 95% CI 0.56–0.92), be small for gestational age (11.4% vs 15.4%, HR 0.68, 95% CI 0.56–0.83) and have severe neonatal complications (6.6% vs 8.2%, HR 0.74, 95% CI 0.57–0.96). Among infants exposed to varenicline in the first trimester, 2.9% had a major congenital anomaly (3.5% in unexposed infants, HR 0.91, 95% CI 0.72–1.15). Varenicline-exposed women were less likely than NRT-exposed women to have an adverse perinatal event (38.7% vs 51.4%, HR 0.58, 95% CI 0.33–1.05). Conclusions: Pregnancy exposure to smoking cessation pharmacotherapies does not appear to be associated with an increased risk of adverse birth outcomes. Lower risk of adverse birth outcomes in varenicline-exposed pregnancies is inconsistent with recommendations that NRT be used in preference to varenicline.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12916-019-1472-9

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Flowchart of pregnancies included in the analyses
Fig. 1 Flowchart of pregnancies included in the analysesCC BY · PubMed Central
Fig. 2 Timing and duration of exposure to a smoking cessation pharmacotherapy in pregnancy. The beginning of each horizontal line indicates the date of dispensing and the length of the line represents the number of days covered by the dispensing. *LMP last menstrual period (estimated)
Fig. 2 Timing and duration of exposure to a smoking cessation pharmacotherapy in pregnancy. The beginning of each horizontal line indicates the date of dispensing and the length of the line represents the number of days covered by the dispensing. *LMP last menstrual period (estimated)CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 48 references

Research works printed but not linked: 10

  1. World Health Organization. WHO recommendations for the prevention and management of tobacco use and second-hand smoke exposure in pregnancy. Geneva: World Health Organization; 2013.
  2. National Centre for Classification in Health. The International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, Australian Modification (ICD-10-AM)-Fifth Edition-Tabular list of diseases and Alphabetic index of diseases. Sydney: National Centre for Classification in Health, Faculty of Health Sciences, The University of Sydney; 2008.
  3. New South Wales Department of Health. Maternity - Towards Normal Birth in NSW. Maternity and Child Health Unit - Strategic Development Division 2010.
  4. Hutchinson M. Western Australia’s mothers and babies, 2012: 30th annual report of the Western Australian midwives notification system; 2015.
  5. WHO Collaborating Centre for Drug Statistics Methodology. ATC alterations from 2005-2019. Geneva: World Health Organization; 2019. https://www.whocc.no/atc_ddd_alterations__cumulative/atc_alterations/?order_by=1. Accessed 7 July 2019
  6. Parsons LS. Performing a 1:N case-control match on propensity sore. Proceedings of the Twenty -Sixth Annual SAS Users Group International Conference; 2004.
  7. European Surveillance of Congenital Anomalies. EUROCAT prevalence data tables. Cases and prevalence (per 10,000 births) of all congenital anomaly subgroups for all registries, from 2012–2016 2018. http://www.eurocat-network.eu/accessprevalencedata/prevalencetables. Accessed 9 Apr 2019.
  8. Pfizer Laboratories. Chantix (full prescribing information) 2019. http://labeling.pfizer.com/ShowLabeling.aspx?id=557. Accessed 2 Apr 2019.
  9. Taylor L, Pym M, Bajuk B, Sutton L, Travis S, Banks C. Validation study NSW midwives data collection 1998. Sydney: NSW Health Department; 2000.
  10. Greenhalgh EM, Scollo MM, Pearce M. 9.1 socio-economic position and disparities in tobacco exposure and use. In: Scollo MM, Winstanley MH, editors. Tobacco in Australia: facts and issues. Melbourne: Cancer Council Victoria; 2018.

Cited by

See all 29

Metadata

Authors
Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A.
Affiliations
  • UNSW Sydney (AU)
  • The University of Western Australia (AU)
  • The University of Sydney (AU)
Corresponding author
Tran, Duong Thuy
Venue
BMC Medicine
Published
2020-02-05
Volume
18
Issue
1
Pages
15-15
ISSN
1741-7015 (ISSN-L)
OpenAlex
W3010465641
Cited by
29
References
47
Citations by year
2026: 5 · 2025: 2 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 5 · 2020: 4
FWCI
3.56
Type
journal article
Language
en
Open access
Licence
Locations
  • BMC Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
  • UWA Profiles and Research Repository (UWA) (submittedVersion, cc-by)
  • UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Opin vísindi (Opin vísindi) (submittedVersion, cc-by)
Funders
  • Australian National Health and Medical Research Council (1028543)
  • National Heart Foundation of Australia (100411)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
Keywords
smoking cessation pharmacotherapy, pregnancy, varenicline, bupropion, nicotine replacement therapy, perinatal complications, major congenital malformations, preterm birth, small for gestational age, maternal smoking, drug safety in pregnancy, Australia, New South Wales, Western Australia, neonatal mortality, neonatal intensive care admission
MeSH terms
Adult, Female, Humans, Pregnancy, Risk Factors, Cohort Studies, Smoking Cessation, Nicotinic Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. https://app.cochat.ai/papers/10.1186/s12916-019-1472-9
The paper
Tran, D. T., Preen, D. B., Einarsdottir, K., Kemp-Casey, A., Randall, D., Jorm, L. R., Choi, S. K. Y., & Havard, A. (2020). Use of smoking cessation pharmacotherapies during pregnancy is not associated with increased risk of adverse pregnancy outcomes: a population-based cohort study. BMC Medicine. https://doi.org/10.1186/s12916-019-1472-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.